 |
 |
 |
 |
 |
 |
Exit of the Year
Description
Cary-based Inveresk Research Group is one of the few drug development companies providing a comprehensive range of pre-clinical and clinical development services on a worldwide basis. Through Inveresk’s pre-clinical and clinical business segments, the company offers a broad range of drug development services, including pre-clinical safety and pharmacology evaluation services, laboratory sciences services and clinical development services. Inveresk’s client base includes major pharmaceutical companies in North America, Europe and Japan, as well as many biotechnology and specialty pharmaceutical companies.
Reasons for winning the award
Inveresk Research Group announced a successful initial public offering (IPO) on June 27, 2002, of 12 million shares, under the NASDAQ ticker symbol IRGI. In June 2003, the company’s stock had produced a 38% return from the original offering price of $13/share, which put Inveresk among the top 15 performing IPOs in the United States during that time period.
Quote
"An IPO in the middle of 2002 was not for the faint hearted! It was made possible by our continuing strength as a high quality, innovative and profitable services group. Our substantial growth and IPO are a reflection of the commitment of our employees and of our strong and successful client relationships. We help them deal with the highest stakes in their industry." -- Alastair McEwan, Executive Vice President
History
Inveresk became a leading provider of pre clinical development services in the mid 1960s and established clinical capabilities in the 1970s. For more than 35 years, it has expanded as a high quality provider of all aspects of drug development services on a global basis. Today it has more than 2,500 employees worldwide. In 2001 Inveresk acquired the ClinTrials group in the US and followed in 2002 with its IPO on NASDAQ.
Photo courtesy of BP Studios.
Home |
Current Winners |
Nomination Form
Categories |
Past Winners |
Register
